» Articles » PMID: 28683846

Beyond the Pill: New Medication Delivery Options for ADHD

Overview
Journal CNS Spectr
Specialties Neurology
Psychiatry
Date 2017 Jul 8
PMID 28683846
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Successful treatment of pediatric disorders has necessitated the development of alternative medication formulations, as children may prefer alternative dosage forms to tablets or capsules. This is especially true for attention-deficit/hyperactivity disorder (ADHD), which is one of the most common chronic pediatric conditions and often involves children with a variety of overlapping physical, psychological, or neurodevelopmental disorders. A special challenge for developing alternative dosage forms for ADHD treatment is the incorporation of a once-daily long-acting formulation. Traditional ADHD medication formulations have been limited, and issues surrounding prescribed dosing regimens-including poor medication adherence, difficulty swallowing, and the lack of dosing titration options-persist in ADHD treatment. In other disease areas, the development of alternative formulations has provided options for patients who have issues with consuming solid dosage forms, particularly children and individuals with developmental disorders. In the light of these new developments, several alternative formulations for ADHD medications are under development or have recently become available. This article reviews the various strategies for developing alternative dosage forms in other disease areas and discusses the application of these strategies in ADHD treatment. Alternative dosage forms may increase medication adherence, compliance, and patient preference and, therefore, improve the overall treatment for ADHD.

Citing Articles

Efficacy and Safety of SPN-812 (Extended-Release Viloxazine) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.

Tan X, Xu Y, Wang S, Li J, Hu C, Chen Z Brain Sci. 2023; 13(12).

PMID: 38137075 PMC: 10742293. DOI: 10.3390/brainsci13121627.


Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree) in Healthy Adult Subjects.

Wang Z, Kosheleff A, Adeojo L, Odebo O, Liranso T, Schwabe S Eur J Drug Metab Pharmacokinet. 2021; 47(1):69-79.

PMID: 34652564 PMC: 8752548. DOI: 10.1007/s13318-021-00729-6.


A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.

Nasser A, Liranso T, Adewole T, Fry N, Hull J, Busse G J Clin Psychopharmacol. 2021; 41(4):370-380.

PMID: 34181360 PMC: 8244935. DOI: 10.1097/JCP.0000000000001404.